Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 6
Open Access

Optimization of Cellular Frequencies in Therapeutic Interventions for Varicose Veins using eMedica: A Pilot Study.

Dr.Vaishali Pagare [1], Dr Pratik Sheshrao Hande [2], Hemant Rohera [3], Dr Deepak Nagpal [4]
[1] Senior Lecturer, Dept of Oral and Maxillofacial Surgery,D Y Patil Dental School, Lohegaon, Pune
[2] Associate Professor, Dept of Oral and Maxillofacial Surgery, D Y Patil Dental School Lohegaon Pune
[3] Director, Research and Development, Rohera Healthcare Technologies Pvt Ltd, Pune, Maharashtra, India
[4] Ex-Dean, Professor and Head, Department of Oral Pathology and Microbiology Swargiya Dadasaheb Kalmegh Smruti Dental College and Hospital, Nagpur, Mahrarashtra, India

Corresponding author:
Dr Deepak Nagpal
Email: deepaknagpal2013@gmail.com

Cite this paper as: Dr.Vaishali Pagare, Dr Pratik Sheshrao Hande, Hemant Rohera, Dr Deepak Nagpal(2024) Optimization of Cellular Frequencies in Therapeutic Interventions for Varicose Veins using eMedica: A Pilot Study. Frontiers in Health *Informatics*, *13(6)*623-627

Abstract
Varicose veins, characterized by enlarged, dilated veins that often cause discomfort and cosmetic concerns, affect a significant portion of the adult population. Traditional treatment modalities, including sclerotherapy, laser therapy, and surgical interventions, present varying degrees of effectiveness and patient satisfaction. This pilot study investigates the use of eMedica, a novel device designed to optimize cellular frequencies, in the therapeutic management of varicose veins. A cohort of 15 patients was recruited to assess the device's safety, efficacy, and impact on patient-reported outcomes.

Introduction

Background

Varicose veins, or chronic venous insufficiency, impact millions of individuals worldwide. The condition results from venous valve incompetence and can lead to symptoms such as pain, swelling, and skin changes. This condition is primarily considered to be a cosmetic problem and widely mistaken to be medically unimportant and given low priority for treatment [2, 3, 4]. However the fact is that the associated pain, swelling, opens ulceration and other morbidities increase cost of its management [2, 3]. The debilitation adds on to the time lost from work and wages [5-7]. In Indian installation it's been diagnosed as a not unusual place surgical trouble in low socio-financial agencies and has additionally led to alternate of career out of compulsion [5]. It isn't sudden that numerous research have discovered that it influences the quality of life (QoL) of the individuals [8, 9]. Although this condition is prevalent among individuals ranging from adolescents to the elderly, its underlying causes remain not fully comprehended. Moreover the type of patients who tend to be more vulnerable to the severity or complications in this condition is also not known [10].
Traditional treatments, while beneficial, often involve invasiveness and variable success rates. Recent

advances in medical technology have prompted innovations in non-invasive therapeutic modalities [11]. The eMedica device leverages specific cellular frequencies aimed at promoting venous health and optimizing blood flow [12-17]. By using frequencies thought to enhance cellular responsiveness, the eMedica device may provide a novel approach for treating varicose veins.

Objective

This study aims to evaluate the safety and preliminary efficacy of the eMedica device for patients with varicose veins, with a focus on alleviating symptoms and improving venous function.

Methods

Study Design

The study adopted a pilot, single-center, open-label design. Patients diagnosed with varicose veins were recruited from a vascular clinic. Inclusion criteria encompassed adults over 18 years, with symptomatic varicosities and no prior interventions within the last three months.

Device Overview

The eMedica device utilizes bioelectromagnetic frequencies that target venous tissues. The device is applied externally, allowing for non-invasive treatment of affected areas.

Participant Enrollment

A total of 15 patients consented to participate in the trial. Baseline assessments included a thorough clinical evaluation and a venous ultrasound to characterize vein morphology and function.

Treatment Protocol

Participants underwent eMedica treatment sessions six times weekly for three consecutive weeks. Each session lasted approximately 30 minutes. Patients maintained a diary logging symptoms and any adverse events experienced during the treatment period.

Outcome Measures

The primary endpoints included:

1. Reduction in symptom severity, as measured by the Visual Analog Scale (VAS).
2. Changes in vein diameter, as assessed through Doppler ultrasound.
3. Patient-reported quality of life metrics, utilizing the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ).

Results

Patient Demographics

The sample consisted of 15 patients, with an average age of 47 years old (range: 30-63). The population was predominantly female (80%). Baseline characteristics indicated moderate to severe symptoms.

Efficacy Outcomes

- **Symptom Reduction:** Post-treatment VAS scores demonstrated a statistically significant reduction, with average scores decreasing from 6.8 pre-treatment to 3.4 post-treatment ($p < 0.01$).
- **Vein Diameter:** Ultrasound measurements revealed a decrease in the diameter of treated veins, with an average reduction of 25% from baseline ($p < 0.05$).
- **Quality of Life Improvements:** CIVIQ scores exhibited significant improvement, with mean scores elevated from 50 pre-treatment to 75 post-treatment ($p < 0.01$).

Figure 1: Pretreatment Vs Postreatment image of the participant

Safety Profile

No serious adverse events occurred during the trial. Minor adverse effects included transient redness and discomfort at the treatment site, which resolved within 24 hours.

Discussion

Conservative therapies for hemorrhoids and varicose veins as described in literature include diet, lifestyle changes, and hydrotherapy which require a high degree of patient compliance to be effective. When conservative hemorrhoid therapy is ineffective, many physicians may choose other non-surgical modalities: injection sclerotherapy, cryotherapy, manual dilation of the anus, infrared photocoagulation, bipolar diathermy, direct current electrocoagulation, or rubber band ligation. Injection sclerotherapy is the non-surgical treatment for primary varicose veins. Non-surgical modalities require physicians to be specially trained, own specialized equipment, and assume associated risks. If a non-surgical approach fails, the patient is often referred to a surgeon. The costly and uncomfortable nature of treatment options often leads a patient to postpone evaluation until aggressive intervention is necessary. Oral dietary supplementation is an attractive addition to the traditional treatment of hemorrhoids and varicose veins. The loss of vascular integrity is associated with the pathogenesis of both hemorrhoids and varicose veins. Several botanical extracts have been shown to improve microcirculation, capillary flow, and vascular tone, and to strengthen the connective tissue of the perivascular amorphous substrate [19]. Oral supplementation with Aesculus hippocastanum, Ruscus aculeatus, Centella asiatica, Hamamelis virginiana, and bioflavonoids may prevent time-consuming, painful, and expensive complications of varicose veins and hemorrhoids [19]. Our pilot study findings suggest that the eMedica device may offer a promising non-invasive treatment modality for varicose veins, with significant reductions in symptoms, enhanced quality of life, and favorable safety outcomes. The use of cellular frequency optimization may play a pivotal role in promoting venous health, aligning with contemporary approaches to venous insufficiency management.

Limitations

This study is limited by its small sample size and lack of a control group. The short follow-up duration precludes assessment of long-term efficacy and safety. Further, randomized controlled trials are essential to substantiate these preliminary findings and delineate the optimal treatment parameters.

Conclusion

In conclusion, this pilot study on the eMedica device indicates its potential as a groundbreaking

therapeutic intervention for managing varicose veins. The promising results warrant further investigation through larger-scale studies to validate efficacy, refine treatment protocols, and establish long-term safety profiles.

Future Directions

Future research should focus on diverse patient populations, long-term follow-up studies, and comparative analyses with established treatment modalities. Investigating the mechanisms by which cellular frequency optimization affects venous function could elucidate additional applications for eMedica in venous medicine.

This report highlights the potential of innovative approaches in treating common vascular conditions and emphasizes the necessity for continued exploration in this evolving field.

References:

1. Aslam MR, Muhammad Asif H, Ahmad K, Jabbar S, Hayee A, Sagheer MS, Rehman JU, Khalid S, Hashmi AS, Rajpoot SR, Sharif A. Global impact and contributing factors in varicose vein disease development. SAGE Open Med. 2022 Aug 25;10:20503121221118992. doi: 10.1177/20503121221118992. PMID: 36051783; PMCID: PMC9425889.
2. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, Lohr JM, McLafferty RB, Meissner MH, Murad MH, Padberg FT, Pappas PJ, Passman MA, Raffetto JD, Vasquez MA, Wakefield TW; Society for Vascular Surgery; American Venous Forum. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011 May;53(5 Suppl):2S-48S. doi: 10.1016/j.jvs.2011.01.079. PMID: 21536172.
3. Farah MH, Nayfeh T, Urtecho M, Hasan B, Amin M, Sen I, Wang Z, Prokop LJ, Lawrence PF, Gloviczki P, Murad MH. A systematic review supporting the Society for Vascular Surgery, the American Venous Forum, and the American Vein and Lymphatic Society guidelines on the management of varicose veins. J Vasc Surg Venous Lymphat Disord. 2022 Sep;10(5):1155-1171. doi: 10.1016/j.jvsv.2021.08.011. Epub 2021 Aug 24. PMID: 34450355.
4. Schoonover JP, King JT, Gray C, Campbell K, Sherman C. 3 alternatives to standard varicose vein treatment. J Fam Pract. 2009 Oct;58(10):522-6. PMID: 19874730.
5. Callam MJ. Epidemiology of varicose veins. Br J Surg. 1994 Feb;81(2):167-73. doi: 10.1002/bjs.1800810204. PMID: 8156326.
6. Mok Y, Ishigami J, Sang Y, Kucharska-Newton AM, Salameh M, Schrack JA, Palta P, Coresh J, Windham BG, Lutsey PL, Folsom AR, Matsushita K. Clinically Recognized Varicose Veins and Physical Function in Older Individuals: The ARIC Study. J Gerontol A Biol Sci Med Sci. 2022 Aug 12;77(8):1637-1643. doi: 10.1093/gerona/glab287. PMID: 34606610; PMCID: PMC9373961.
7. Smyth RM, Aflaifel N, Bamigboye AA. Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database Syst Rev. 2015 Oct 19;2015(10):CD001066. doi: 10.1002/14651858.CD001066.pub3. PMID: 26477632; PMCID: PMC7050615.
8. Kurz X, Lamping DL, Kahn SR, Baccaglini U, Zuccarelli F, Spreafico G, Abenhaim L; VEINES Study Group. Do varicose veins affect quality of life? Results of an international population-based study. J Vasc Surg. 2001 Oct;34(4):641-8. doi: 10.1067/mva.2001.117333. PMID: 11668318.
9. van Korlaar I, Vossen C, Rosendaal F, Cameron L, Bovill E, Kaptein A. Quality of life in venous disease. Thromb Haemost. 2003 Jul;90(1):27-35. PMID: 12876622.
10. National Clinical Guideline Centre (UK). Varicose Veins in the Legs: The Diagnosis and Management of Varicose Veins. London: National Institute for Health and Care Excellence (NICE); 2013 Jul. PMID: 25535637.

11. Kolimi P, Narala S, Nyavanandi D, Youssef AAA, Dudhipala N. Innovative Treatment Strategies to Accelerate Wound Healing: Trajectory and Recent Advancements. Cells. 2022 Aug 6;11(15):2439. doi: 10.3390/cells11152439. PMID: 35954282; PMCID: PMC9367945.
12. Dr Deepak Nagpal, & Hemant Rohera. (2023). Emedica: A New Approach To Diabetes Management. *Journal for ReAttach Therapy and Developmental Diversities*, *6*(8s), 1011–1016. https://doi.org/10.53555/jrtdd.v6i8s.3155
13. Hemant Rohera, Dr Ramesh Chouhan, Dr. Mrunali Jambhulkar, Dr. Vaishali Khatri, & Dr. Deepak Nagpal. (2024). "Emedica: A Noninvasive Device to Improve Insulin Sensitivity in Type 2 Diabetes Patients". *Revista Electronica De Veterinaria*, *25*(1), 2469 - 2473. https://doi.org/10.69980/redvet.v25i1.1256
14. Dr Deepak Nagpal, Hemant Rohera. Evaluating the Efficacy of E-medica: A Cross-Sectional Analysis of Its Role in Hypertension Management. Afr. J. Biomed. Res. Vol. 27 (September2024); 1823-1827. DOI: https://doi.org/10.53555/AJBR.v27i1S.1721
15. Dr Pratik Sheshrao Hande, Hemant Rohera, Dr. Gulam Saidunnisa Begum+, Dr Deepak Nagpal, Dr Srinivasa Gowda, Dr B K Manjunatha Goud. Enhancing Patient Outcomes with Emedica Technology in the Fight Against COVID-19: A Health and Medicine Approach. Afr. J. Biomed. Res. Vol. 27(September2024); 2861-2878. DOI:https://doi.org/10.53555/AJBR.v27i1S.1919.
16. Hemant Rohera, Dr Ramesh Chouhan , Dr Deepak Nagpal. Revolutionizing Osteoarthritis Management with eMedica micro-current therapy. NeuroQuantology, October 2024, Volume 22, Issue 5 ,174-178;doi: 10.48047/nq.2024.22.5.nq25018.
17. Dr K. Rajashekar , Dr Hemavathi Patil , Hemant Rohera , Dr Ramesh Chouhan , Dr Deepak Nagpal. Use of Electron Therapy Device eMedica in the Management of Chronic Lymphocytic Leukemia: A case report. Frontiers in Health Informatics Vol. 13 No. 3 (2024) 2701-2704.
18. MacKay D. Hemorrhoids and varicose veins: a review of treatment options. Altern Med Rev. 2001 Apr;6(2):126-40. PMID: 11302778.
19. Sakshi Dhiman, Rohit Kumar Nadda, Prerna Bhardwaj, Medicinal herbs from Western Himalayas for hemorrhoids treatment: A review correlating traditional knowledge with modern therapeutics,Pharmacological Research - Modern Chinese Medicine,Volume 9,2023,100334,ISSN 2667-1425,doi.org/10.1016/j.prmcm.2023.100334.